Livzon Acquires 67.87% Stake in Imexpharm (IMP) for $240M
This Aveluro analysis covers IMP (Dược phẩm Imexpharm) in the Dược phẩm sector. The classified event type is m a announcement, with positive sentiment and a deterministic market-impact score of 8.4/10. Aveluro classifies this story as a positive catalyst in the stock's news coverage. Source coverage came from VnExpress - Kinh doanh, classified as a primary/top-tier source.
Follow this event and trade Vietnam stocks
Use the broker guide to compare Vietnam market access before acting on this news.
Aveluro may earn a commission from broker partners. Market data and broker availability can change; confirm access before opening an account.
Overview
Chinese pharmaceutical giant Livzon Group, through its subsidiary Lian SGP Holding, has completed the acquisition of a 67.87% stake in Imexpharm (IMP), Vietnam’s leading antibiotic manufacturer. The deal, valued at nearly VND 6,000 billion (approximately $240 million), positions Livzon as the controlling shareholder and is expected to enhance IMP’s R&D capabilities and product portfolio.
Key Facts
- Livzon acquired over 104.5 million IMP shares, representing 67.87% of charter capital.
- The offer price was VND 57,400 per share, a 22.5% premium over the closing price on the announcement date.
- Total transaction value reached nearly VND 6,000 billion (about $240 million).
- Imexpharm was valued at approximately VND 8,842 billion ($338 million) based on the offer price.
- Livzon initially registered to buy up to 120 million shares (78% of capital) but purchased 15.5 million fewer shares.
- Imexpharm holds a 10% market share in Vietnam’s antibiotic segment as of 2025.
- The seller side included SK Investment, Binh Minh Investment JSC, and KBA Investment JSC, though specific sellers were not disclosed.
What Happened
Lian SGP Holding, a subsidiary of Livzon Pharmaceutical Group, has completed the purchase of over 104.5 million shares of Imexpharm (IMP), securing a 67.87% controlling stake. The transaction was executed via a public tender offer initially announced in mid-January, which targeted up to 120 million shares (nearly 78% of capital). The final purchase was slightly lower than the initial registration.
At the annual general meeting in late April, Imexpharm CEO Tran Thi Dao stated that Livzon’s strong R&D capabilities and global quality standards, including FDA approvals for some injectable drugs, would help Imexpharm expand into high-tech product lines and improve competitiveness. Livzon has committed to maintaining stable business operations and transferring advanced technologies.
Market Context
Imexpharm (IMP) closed at VND 46,850 on May 12, 2026, with thin volume of 24,100 shares. The stock is listed on HOSE. The acquisition price of VND 57,400 represents a 22.5% premium, reflecting the strategic value Livzon places on IMP’s domestic leadership in antibiotics and its established partnerships with global pharma firms such as Sandoz, Pharmascience, and Sanofi.
Strategic Significance
This acquisition marks a significant consolidation in Vietnam’s pharmaceutical sector, bringing a top Chinese pharma group into a leading domestic player. Livzon’s deep R&D pipeline and global reach can help Imexpharm move beyond antibiotics into higher-value therapeutic areas, leveraging existing manufacturing lines. The deal also underscores foreign investor appetite for Vietnamese healthcare assets with strong market positions and regulatory compliance.
What to Watch
- Integration progress and any changes to Imexpharm’s management or board composition in Q2 2026.
- Launch of new products or technology transfers from Livzon, particularly in biologics or injectables.
- Imexpharm’s next quarterly earnings report for signs of revenue or margin improvement from the partnership.
- Potential further foreign ownership adjustments as Livzon may seek to increase its stake.
- Regulatory approvals for any new drug registrations stemming from the collaboration.